SHH and Mobius syndrome: MicroRNA-125a expression could represent a promising prognostic factor and a potential therapeutic target in non-WNT/non-SHH molecular group which represents the most common and the most heterogeneous group of pediatric MBs coupled with the highest rates of disseminated disease.